Medytox Appoints Actor Park Hyungsik as Global Ambassador... Joins 12th Anniversary NEURAMIS Campaign

Park Hyungsik Appointed as Global Ambassador for NEURAMIS
Medytox to Launch New Campaign Celebrating 12th Anniversary

On July 3, Medytox, a biopharmaceutical company, announced that actor Park Hyungsik has been appointed as the global ambassador for Medytox. The company is set to soon unveil a new advertising campaign celebrating the 12th anniversary of its premium hyaluronic acid (HA) filler, NEURAMIS, featuring Park Hyungsik as the newly selected global ambassador.

Actor Park Hyungsik appointed as the global ambassador of Medytox. Photo by Medytox

Actor Park Hyungsik debuted in 2010 as a member of ZE:A and has since expanded his career as an actor, becoming one of the most sought-after stars. Most recently, he delivered a powerful performance as Seo Dongju in the SBS Friday-Saturday drama "Treasure Island," which concluded to high popularity. This has solidified his strong fan base not only in Korea but also globally.

Medytox plans to launch the new advertising campaign for NEURAMIS, which marks its 12th anniversary, across various channels including TV commercials, print (magazine) ads, and YouTube, in collaboration with Park Hyungsik. In addition, Medytox will sequentially release related videos such as the new campaign advertisement, behind-the-scenes footage, and Shorts through its official YouTube channel.

A Medytox representative stated, "We expect that the future vision of Medytox, which is emerging as a global company, and the various charms of actor Park Hyungsik will create significant synergy through diverse activities," adding, "We will carry out a wide range of marketing activities for the premium filler brand NEURAMIS, which celebrates its 12th anniversary, together with our global ambassador."

Meanwhile, the premium hyaluronic acid filler NEURAMIS series uses high-quality hyaluronic acid raw materials certified by the U.S. Food and Drug Administration (FDA) Drug Master Files (DMFs) and the European Directorate for the Quality of Medicines (EDQM). The product is managed under stricter standards than the European Pharmacopoeia (Ph.Eur), which enhances its safety profile.

Furthermore, based on Medytox's proprietary technology, the safety of the cross-linking reaction has been improved, and the residual amount of cross-linking agent (BDDE) has been reduced below the standard threshold, minimizing the potential for side effects. The NEURAMIS series is currently exported to 35 countries worldwide, and in May, two new products, NEURAMIS Heart and NEURAMIS Skin Enhancer, were added, completing a lineup of six products in total.